Carna Biosciences (TSE:4572) EBIT: 円-1,054.9 Mil (TTM As of Dec. 2025)


TSE:4572 Carna Biosciences Inc TSE:4572
25 GF Score
Price 円314.00
GF Value 円175.60
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences EBIT?

Carna Biosciences TSE:4572 -3.68% 25 EBIT is 円-1,054.9 Mil as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 25/100 and a GF Value™ of 円175.60 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Carna Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was 円0.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-1,054.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Carna Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. Carna Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Carna Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -15.65%.


Carna Biosciences  (TSE:4572) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Carna Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (437.805 + 571.638)/ 2 )
=0/504.7215
=0.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1635.585 - 137.211 - ( 1060.569 - max(0, 184.225 - 1589.155+1060.569))
=437.805

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1229.648 - 141.221 - ( 516.789 - max(0, 168.07 - 1175.527+516.789))
=571.638

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Carna Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0 + max(362.767, 0)) + (0 + max(507.569, 0)) )/ 2 )
=0/( ( 362.767 + 507.569 )/ 2 )
=0/435.168
=0.00 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(71.94 + 163.596 + 293.05) - (137.211 + 0 + 28.608)
=362.767

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(100.528 + 154.101 + 404.109) - (141.221 + 0 + 9.948)
=507.569

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Carna Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-1054.922/6740.915
=-15.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Carna Biosciences EBIT Related Terms


Carna Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences EBIT Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -528.57 -1,318.09 -1,127.40 -2,171.02 -2,159.80

Carna Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -498.45 -556.00 0.00 -498.93

TSE:4572 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Carna Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's EV-to-EBIT falls into.


TSE:4572
25GF Score
Carna Biosciences Inc TSE:4572
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,054.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-1,054.9 Mil mean?
Carna Biosciences (TSE:4572) has a EBIT of 円-1,054.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Carna Biosciences.
Is Carna Biosciences' EBIT too high?
Carna Biosciences' current EBIT is 円-1,054.9 Mil. Overall, Carna Biosciences has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' EBIT compare to VRTX and REGN?
Carna Biosciences' EBIT of 円-1,054.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Carna Biosciences. Carna Biosciences's current EBIT is 円-1,054.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円175.60, compared to a current price of 円314.00 — trading 78.8% above its estimated fair value. The current EBIT is 円-1,054.9 Mil. Carna Biosciences' overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current EBIT is 円-1,054.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円314.00 is trading 78.8% above its estimated GF Value™ of 円175.60. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • EBIT: 円-1,054.9 Mil
  • GF Value™: 円175.60 vs. price of 円314.00 (78.8% above fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
25GF Score

Get the complete analysis for TSE:4572

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円314.00
Price
円175.60
GF Value